×
About 175,476 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  83,011 results

miRNAs expression signature potentially associated with lymphatic dissemination in loca...
https://doi.org/10.1186/s12920-020-00788-9
BMC Medical Genomics; Pudova EA, Krasnov GS et. al.

Sep 19th, 2020 - Prostate cancer is one of the most common and socially significant cancers among men. The aim of our study was to reveal changes in miRNA expression profiles associated with lymphatic dissemination in prostate cancer and to identify the most promi...

Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary P...
https://doi.org/10.1016/j.urolonc.2020.08.027
Urologic Oncology; Fi SW, Trpkov K et. al.

Sep 19th, 2020 - To survey urologic clinicians regarding interpretation of and practice patterns in relation to emerging aspects of prostate cancer grading, including quantification of high-grade disease, cribriform/intraductal carcinoma, and impact of magnetic re...

Q&A: John Carpten on the Genomics of Cancer Disparities.
https://doi.org/10.1158/2159-8290.CD-ND2020-015
Cancer Discovery;

Sep 19th, 2020 - John Carpten, PhD, of the University of Southern California's Keck School of Medicine in Los Angeles, discusses his research on genomic differences that may underlie disparities in incidence and mortality in Black patients with prostate cancer or ...

Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes ...
https://doi.org/10.1002/pros.24074
The Prostate REFERENCES; Harshman LC, Wang VX et. al.

Sep 19th, 2020 - The immunosuppressive cytokine interleukin- 8 (IL-8), produced by tumor cells and some myeloid cells, promotes inflammation, angiogenesis, and metastasis. In our discovery work, elevated serum IL-8 at androgen deprivation therapy (ADT) initiation ...

Biodistribution and dosimetry of a single dose of albumin-binding ligand 177LuLu-PSMA-A...
https://doi.org/10.1007/s00259-020-05022-3
European Journal of Nuclear Medicine and Molecular Imaging; Kramer V, Fernández R et. al.

Sep 19th, 2020 - PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was...

see more →

Guidelines  373 results

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cance...
https://doi.org/10.1016/j.euf.2020.05.014
European Urology Focus; Siebert AL, Lapping-Carr L et. al.

Jul 16th, 2020 - Although substantial literature examining the neuropsychiatric consequences of androgen deprivation therapy (ADT) exists, there are no clinical guidelines to inform providers about the specific risk of depression, suicide, and dementia for prostat...

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achiev...

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
https://doi.org/10.1016/j.annonc.2020.06.011
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Parker C, Castro E et. al.

Jun 30th, 2020 - Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Parker C,Castro E,Fizazi K,Heidenreich A,Ost P,|

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/neal-shore-on-relugolix-vs-leuprolide-for-advanced-prostate-cancer/

May 31st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testoste...

see more →

Drugs  321 results see all →

Clinicaltrials.gov  87,879 results

miRNAs expression signature potentially associated with lymphatic dissemination in loca...
https://doi.org/10.1186/s12920-020-00788-9
BMC Medical Genomics; Pudova EA, Krasnov GS et. al.

Sep 19th, 2020 - Prostate cancer is one of the most common and socially significant cancers among men. The aim of our study was to reveal changes in miRNA expression profiles associated with lymphatic dissemination in prostate cancer and to identify the most promi...

Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary P...
https://doi.org/10.1016/j.urolonc.2020.08.027
Urologic Oncology; Fi SW, Trpkov K et. al.

Sep 19th, 2020 - To survey urologic clinicians regarding interpretation of and practice patterns in relation to emerging aspects of prostate cancer grading, including quantification of high-grade disease, cribriform/intraductal carcinoma, and impact of magnetic re...

Q&A: John Carpten on the Genomics of Cancer Disparities.
https://doi.org/10.1158/2159-8290.CD-ND2020-015
Cancer Discovery;

Sep 19th, 2020 - John Carpten, PhD, of the University of Southern California's Keck School of Medicine in Los Angeles, discusses his research on genomic differences that may underlie disparities in incidence and mortality in Black patients with prostate cancer or ...

Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes ...
https://doi.org/10.1002/pros.24074
The Prostate REFERENCES; Harshman LC, Wang VX et. al.

Sep 19th, 2020 - The immunosuppressive cytokine interleukin- 8 (IL-8), produced by tumor cells and some myeloid cells, promotes inflammation, angiogenesis, and metastasis. In our discovery work, elevated serum IL-8 at androgen deprivation therapy (ADT) initiation ...

Biodistribution and dosimetry of a single dose of albumin-binding ligand 177LuLu-PSMA-A...
https://doi.org/10.1007/s00259-020-05022-3
European Journal of Nuclear Medicine and Molecular Imaging; Kramer V, Fernández R et. al.

Sep 19th, 2020 - PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was...

see more →

News  3,723 results

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achiev...

Roche prostate cancer hopeful has mixed results in late-stage trial
https://www.reuters.com/article/us-roche-trial/roche-prostate-cancer-hopeful-has-mixed-results-in-late-stage-trial-idUSKBN23Q0QI

Jun 19th, 2020 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann ZURICH (Reuters) - Roche had mixed results for a late-stage trial of an experimental drug for prostate cancer, ...

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/neal-shore-on-relugolix-vs-leuprolide-for-advanced-prostate-cancer/

May 31st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testoste...

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-morris-on-the-impact-of-psma-targeted-imaging-on-clinical-management-of-prostate-cancer/

May 31st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate can...

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy
https://ascopost.com/videos/asco20-virtual-scientific-program/rana-mckay-on-intense-adt-before-radical-prostatectomy/

May 31st, 2020 - Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of pati...

see more →

Patient Education  169 results see all →